Dermata Therapeutics (DRMA) Return on Capital Employed (2021)
Dermata Therapeutics (DRMA) posted quarterly Return on Capital Employed of 70.54% for Q4 2021, up 24.34% quarter-over-quarter from 93.23% in Q3 2021.
Dermata Therapeutics (DRMA) Return on Capital Employed (2021) Analysis & Trends
Dermata Therapeutics' Return on Capital Employed history runs 1 years deep, the most recent figure standing at 70.54% for Q4 2021.
- In Q4 2021, Return on Capital Employed changed N/A year-over-year to 70.54%; the TTM figure through Dec 2021 stood at 70.54% (changed N/A YoY), while the FY2021 annual figure was 170.88%, changed N/A from the prior year.
- Return on Capital Employed for Q4 2021 stood at 70.54%, up from 93.23% in the prior quarter.
- The five-year high for Return on Capital Employed was 70.54% in Q4 2021, with the low at 93.23% in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -70.54% |
| Sep 30, 2021 | -93.23% |